The American Cancer Society (ACS) advises receiving annual digital rectal exams (DREs) and prostate-specific antigen (PSA) tests, starting at age 45 years for at-risk groups comprising individuals with first degree relatives diagnosed with PC at an early age. This evidence concerns the gene KLK3 and pachyonychia congenita.